{
  "question": "月经前，乳房胀痛，腋窝痛，马上就要来月经了，发现在挤压右侧乳头时，有一点点白色得液体冒出来。为什么会有白色得液体冒出来呢？我很怕自己得乳腺癌。我马上就要来月经了，现在去医院检查会不会对检查结果有影响。可是我现在很急，很担心。",
  "retrieved_context": "",
  "ai_answer": "retrieved_context:\n{\n  \"retrieved_context\": [\n    {\n      \"content\": \"Oncogenic activation of RAS/MAPK is associated with a significant reduction in tumor-infiltrating lymphocytes (TILs) and lower survival in TNBC patients, while concomitant MEK inhibition and antiPD1/PD-L1 immunotherapy augmented anti-tumor immunity in preclinical TNBC models (Loi et al., 2016)In addition to the ERK pathway, MAP3K1 can regulate MAPK-JNK signaling through phosphorylation of substrates such as MAP2K4Relatively frequent somatic mutations occur in MAP2K4 and MAP3K1 in luminal cancers (12% in total), often coincident with PIK3CA mutationsWhile JNK pathway activation is predictive of chemotherapy sensitivity in TNBC, recent evidence suggests JNK signaling fosters an immunosuppressive TME to drive tumor progression, implicating JNK-targeted immunotherapy as a potential treatment strategy for TNBC (Semba et al., 2022). Cyclin D1-CDK4/6-RB axis The cyclin D1-CDK4/6-RB axis is the pivotal regulator of the G1-S transition of the cell cycle\",\n      \"title\": \"Deciphering breast cancer_ from biology to the clinic.pdf\"\n    },\n    {\n      \"content\": \"n engl j med 375;8 nejm.org August 25, 2016 719 70-Gene Signature in Early Breast Cancer clinical and genomic results were advised not to receive adjuvant chemotherapy, whereas patients who were categorized as having high-risk disease by both tests were advised to receive chemotherapy. Patients with discordant results (i.e., either high clinical risk and low genomic risk or low clinical risk and high genomic risk) were randomly assigned to the chemotherapy group or the no-chemotherapy group on the basis of either the clinical result or the genomic resultThe treatment randomization used a minimization technique that was stratified according to institution, risk group, hormone-receptor status (ER-positive or progesterone [PR]-positive vs ER-negative and PR-negative), nodal involvement (yes or no), age (<50 years vs≥50 years), HER2 status (HER2-positive vsHER2-negative vsunknown), axillary treatment (sentinel node only vs dissection), and type of surgery (mastectomy vs\",\n      \"title\": \"CSCO BC指南参考文献29.pdf\"\n    },\n    {\n      \"content\": \"Many other reviews reached similar conclusions, reporting positive moderate effect sizes of mind-body interventions on anxiety and distress in cancer.45, 98 Risk/Benefit assessment of meditation interventions: Meditation therapies pose very little risk to participants in this type of interventionFew adverse events have been reported in any trials, but there has been recent interest within the meditation research community in exploring adverse reactions to intensive meditation practice, particularly in vulnerable individuals.99, 100 Typically, potential participants are screened through individual orientation interviews prior to joining meditation group programs, and participants who have serious mental health issues are often re-directed to individual counseling or psychiatric intervention prior to or concomitant with mind-body intervention participation\",\n      \"title\": \"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment.pdf\"\n    },\n    {\n      \"content\": \"If more than 50% of the constituent items on the QLQ-C30 and QLQ-BR23 scales were completed, a prorated score was computed.17 For scales with less than 50% of the items completed, the scale was considered missing. Mean change of the linear transformed scores from baseline—and SEs—were computed for each assessment timepoint. RESULTS From June 2014 to June 2015, 444 patients were randomly assigned (T-DM1+P, n = 223; TCH+P, n = 221; Fig 1 and Appendix Table A1, online only), and all but two patients in the TCH+P arm received one or more dose of study medication.12 Baseline characteristics were balanced between arms (Appendix Table A2, online only)Hormone receptor–positive disease was present in 62.2% of patients, and 83.1% had clinical stage IIA to IIIA disease, 66.4% were white, and 25.2% were Asian\",\n      \"title\": \"CSCO BC指南参考文献11.pdf\"\n    },\n    {\n      \"content\": \"Both groups also received concurrent intravenous trastuzumab, with an initial loading dose of 8 mg/kg and a maintenance dose of 6 mg/kg on day 1, as well as intravenous pertuzumab with a loading dose of 840 mg and a maintenance dose of 420 mg on day 1 This report is the final analysis of the primary endpoint, pathological complete response (ypT0/is ypN0), analysed in all patients who started treatment (modified intention to treat)The trial is registered with ClinicalTrials.gov, NCT04547907, and follow-up of the adjuvant phase is ongoing. Findings Between Sept 20, 2020, and March 1, 2023, 789 patients were screened for eligibility, 689 of whom were randomly assigned (343 to the nab-paclitaxel group and 346 to the docetaxel plus carboplatin group)All 689 patients were Asian women669 patients received at least one dose of the study treatment and were included in the full analysis set (332 in the nab-paclitaxel group and 337 in the docetaxel plus carboplatin group)\",\n      \"title\": \"CSCO BC指南参考文献13.pdf\"\n    },\n    {\n      \"content\": \"Recently, a new subclass of malignant cells within tumors called the cancer stem cells (CSCs) are observed and associated with tumor initiation, escape and recurrenceThis small population of cells, which may develop from stem cells or progenitor cells in normal tissues, have self-renewal abilities and are resistant to conventional therapies such as chemotherapy and radiotherapy [13-15]Breast cancer stem cells (bCSCs) were first identified by Ai Hajj and even as few as 100 bCSCs could form new tumors in the immunocompromised mice [16]bCSCs are more likely to originate from luminal epithelial progenitors rather than from basal stem cells [17]Signaling pathways including Wnt, Notch, Hedgehog, p53, PI3K and HIF are involved in the self-renewal, proliferation and invasion of bCSCs [18-21]\",\n      \"title\": \"Risk Factors and Preventions of Breast Cancer.pdf\"\n    }\n  ]\n}\nanswer:\n白色乳头溢液在月经前出现可能有多种原因。其中生理性原因较为常见，比如乳腺增生，在月经前体内激素水平变化可能导致乳腺组织增生，进而出现乳头溢液情况；另外，泌乳素轻度升高也可能引起这种现象。不过为了明确原因，建议你尽快前往医院乳腺科就诊。关于月经对检查的影响，一般来说，若只是进行乳腺超声等检查，月经前通常影响不大；但如果要检查泌乳素水平，可能建议在月经来潮后的3 - 5天进行会更准确。你现在不要过度恐慌，很多情况可能是良性的，及时就医检查才能明确具体原因并采取相应措施。同时，要尽量保持心情放松，避免过度焦虑，因为心理因素也可能影响乳腺状况。可以先调整好心态，尽快安排就医检查。",
  "ref_answer": "乳头溢液是乳房病的常见症状，溢乳的原因是因为体内催乳素分泌过多。建议你月经过后7至14天去医院进行乳透，看看是否有乳腺疾病，发现问题及时治疗。"
}